Clinical analysis of Gefitinib in the treatment of stage IV lung adenocarcinoma with unknown EGFR gene mutations

Thoracic Cancer

Volumn 4, Issue 4, 2013, Pages 433-439

  Li, Rong ^a   Lou, Yuqing ^a   Zhang, Yanwei ^a   Shi, Chunlei ^a   Xiong, Liwen ^a   Gu, Aiqin ^a   Han, Baohui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Drug toxicity; EGFR gene mutation; Gefitinib; Lung cancer; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; INTERSTITIAL PNEUMONIA; LIVER DYSFUNCTION; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; TREATMENT RESPONSE;

EID: 84887009968     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/1759-7714.12044     Document Type: Article

References (10)

1. Wang T, Nelson RA, Bogardus A, Grannis FW Jr. Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer 2010; 116: 1518-1525.
2. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005; 117: 294-299.
3. Kim HR, Shim HS, Chung JH etal. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 2012; 118: 729-739.
4. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: non-small cell lung cancer. 2012; Version 1. [Cited 12 Feb 2013.] Available from URL: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
5. Tam AL, Kim ES, Lee JJ etal. Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol 2013; 8: 436-442.
6. Asami K, Koizumi T, Hirai K etal. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study. Clin Lung Cancer 2011; 12: 387-392.
7. Kobayashi M, Matsui K, Katakami N etal. Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: west Japan Thoracic Oncology Group Study 0402. Jpn J Clin Oncol 2011; 41: 948-952.
8. Inoue A, Kobayashi K, Usui K etal. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009; 27: 1394-1400.
9. Sanford M, Scott LJ. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Drugs 2009; 69: 2303-2328.
10. Bianchini D, Jayanth A, Chua YJ, Cunningham D. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker. Clin Colorectal Cancer 2008; 7: 33-43.